ReviewMagyar onkologia2026
[Oncologist's perspective from sentinel node biopsy of melanoma - three decades of experience].
Review in Magyar onkologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sentinel lymph node biopsy was the first procedure to become the standard of care in the surgical treatment of melanoma patients, serving as a key procedure for determining the pathological stage of the disease. Thirty years ago, at the Albert Szent-Györgyi Clinical Center of the University of Szeged, we were among the pioneers in introducing sentinel lymph node biopsy for patients with melanoma in Hungary. In this publication, we summarize our experience gained during the treatment of two and a half thousand melanoma patients, based on our previously published reports on the subject. Our data support that sentinel lymph node biopsy remains the most important guide for oncologists in determining adjuvant treatment for patients. The management of melanoma patients should continue to be based on decisions made by multidisciplinary teams in specialized centers, where all diagnostic and therapeutic modalities are available to implement personalized therapies.
Indexed as
Identifiers
42730999PMC13577717What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.